<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04959760</url>
  </required_header>
  <id_info>
    <org_study_id>CLDG-0511</org_study_id>
    <nct_id>NCT04959760</nct_id>
  </id_info>
  <brief_title>BinaxNow COVID-19 IgG Rapid Test Device and Antibody Self Test</brief_title>
  <official_title>Clinical Evaluation of the BinaxNOW™ COVID-19 IgG Rapid Test Device and the BinaxNOW™ COVID-19 Antibody Self Test Clinical Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Rapid Diagnostics Jena GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Rapid Diagnostics Jena GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Performance evaluation of the BinaxNOW™ COVID-19 IgG Rapid Test Device (Professional Use) and&#xD;
      with BinaxNOW™ COVID-19 Antibody Self Test wehn used with fingerstick capillary whole blood&#xD;
      and plasma samples. The BinaxNOW™ Antibody Tests are lateral flow tests that measure&#xD;
      SARS-CoV-2 IgG antibodies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Operator of the device will be blinded to the outcome</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical performance of the BinaxNOW™ COVID-19 IgG Rapid Test</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>to evaluate the clinical performance of the BinaxNOW™ COVID-19 IgG Rapid Test Device when used by a professional user.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical performance of the BinaxNOW™ COVID-19 Antibody Self-Test</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>to evaluate the clinical performance of the BinaxNOW™ COVID-19 Antibody Self-Test when used by a lay person.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Professional user usability</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Evaluation of the usability of the BinaxNOW™ COVID-19 IgG Rapid Test Device when used by a Professional User</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self Test user usability</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Evaluation of the usability of the BinaxNOW™ COVID-19 Antibody Self-Test when used by a lay person.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matrix Equivalence Professional Use</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Validation of the Matrix Equivalence between the Fingerstick Whole Blood and Plasma samples when used with the BinaxNOW COVID-19 IgG Rapid Test Device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic sensitivity and specificity</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>To determine the diagnostic sensitivity, specificity and overall agreement of the BinaxNOW™ COVID-19 Antibody Self Test as performed by lay users in comparison with the BinaxNOW™ COVID-19 IgG Rapid Test Device as performed by professional user.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>COVID-19 Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>BinaxNow Covid-19 Antibody test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The BinaxNOW™ Antibody Tests measure SARS-CoV-2 S-IgG antibodies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2.</intervention_name>
    <description>The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2 in fingestick capillary blood and plasma samples.</description>
    <arm_group_label>BinaxNow Covid-19 Antibody test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant is 18 years of age or older.&#xD;
&#xD;
          2. Evaluable individuals with a prior confirmed SARS-CoV-2 infection with prior COVID-19&#xD;
             symptoms with symptoms onset &gt; 14 days prior to the study, or symptoms onset 8-14 days&#xD;
             prior to the study, or symptoms onset 0-7 days prior to study.OR&#xD;
&#xD;
             Evaluable individuals confirmed negative by SARS-CoV-2 RT-PCR using a sample obtained&#xD;
             within 7 days prior to or on the day of the study.&#xD;
&#xD;
          3. Participant agrees to complete all aspects of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant has already participated in this study on a previous occasion.&#xD;
&#xD;
          2. Participant is enrolled in a study to evaluate a new drug.&#xD;
&#xD;
          3. Participant has a visual impairment that cannot be restored using glasses or contact&#xD;
             lenses.&#xD;
&#xD;
          4. Participant is unable or unwilling to provide informed consent.&#xD;
&#xD;
          5. Participant is a vulnerable person as deemed unfit for the study by the Principal&#xD;
             Investigator.&#xD;
&#xD;
          6. Participant has a condition deemed unfit to safely perform the test by the&#xD;
             investigator.&#xD;
&#xD;
          7. Participant is a practising health-care professional or laboratory scientist /&#xD;
             technician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Kordowich</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon Kordowich</last_name>
    <phone>+49 162-136-8985</phone>
    <email>simon.kordowich@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenchi Lin</last_name>
    <phone>+353873946587</phone>
    <email>wenchi.lin@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Moy, MD</last_name>
      <phone>312-942-6352</phone>
    </contact>
    <investigator>
      <last_name>James Moy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Woods</last_name>
      <phone>919-668-7174</phone>
    </contact>
    <investigator>
      <last_name>Christopher Woods, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urgent Care Clinical Trials</name>
      <address>
        <city>Powdersville</city>
        <state>South Carolina</state>
        <zip>29611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Harris, MD</last_name>
      <phone>864-307-8672</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urgent Care Clinical Trials at Complete Health Partners</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Mickiewicz, MD</last_name>
      <phone>629-203-7858</phone>
    </contact>
    <investigator>
      <last_name>Marc Mickiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urgent Care Clinical Trials</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiwali Rai, MD</last_name>
      <phone>214-871-7000</phone>
    </contact>
    <investigator>
      <last_name>Shiwali Rai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

